At 2023 NACLC, Xiaohan Hu presented “Real-World Patients Characteristics, Biomarker Testing & Adjuvant Therapy for Resected NSCLC at US Oncology Clinics, 2019-2023”
Read More
At the 2023 NACLC, Benjamin Lok, MD, FRCPC, presented a radiation “mini-debate” focused on the “Goldie Locks Effect.”
Read More
At the 2023 NACLC, Florian Fintelman, MD, presented a recap of data on the use of artificial intelligence for lung cancer risk prediction on chest CT.
Read More
Forget the O’Hare food kiosks and grab lunch at one of these locations instead, all within easy walking distance from the Chicago Marriott Downtown Magnificent Mile
Read More
Don’t miss the 2023 NACLC closing keynote—Perioperative Therapy—to be given by Jonathan Spicer, MD, PhD, 11:15 a.m.-12:15 p.m., Sunday, December 3, 2023.
Read More
Make the most of your final day at the 2023 NACLC conference—use the program information below to plan your schedule:
Read More
A curated eBook featuring ESMO 2023: eNSCLC-focused studies, findings, and expert opinions.
Read More
Many barriers exist in the recruitment for diabetic macular edema clinical trials of patients of minority racial and ethnic backgrounds.
Read More
Key risk factors for progression independent of relapse activity in relapsing-remitting MS include age and longer disease duration.
Read More
More targeted, higher efficacious medications can drastically reduce the risk for accruing disability in newly diagnosed patients with MS.
Read More
2023 NACLC is taking place in Chicago’s famous “Magnificent Mile” district, so be sure to set aside a little time for exploring!
Read More
Check out the fascinating array of topics to be covered during 2023 NACLC satellite CME symposia!
Read More
The IASLC 2023 North America Conference on Lung Cancer (NACLC) runs December 1-3, 2023, at the...
Read More
For patients with primary progressive MS, age is a particularly important factor that predicts disease activity.
Read More
The benefits of interleukin inhibitors vary by agent and include increased drug survival and earlier attainment of Psoriasis Area Severity Index scores.
Read More
Aflibercept 8 mg shows efficacy for patients with diabetic macular edema regardless of sex, age, and race/ethnicity.
Read More
Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.
Read More
Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.
Read More
Fractal dimensions represent a promising biomarker for assessing retinal vascular damage.
Read More
Dermatologists must be knowledgeable about differences among people of color with psoriasis and to tailor their approach to diagnosis and treatment accordingly.
Read More
